Opthea Wet AMD Program to be Presented at Innovate Retina

OPT 10.10.2024

Full Press ReleaseSEC FilingsOur OPT Tweets

About Gravity Analytica

Recent News

  • 02.05.2025 - Opthea Investor Day - Melbourne
  • 02.03.2025 - Opthea Investor Day - Sydney
  • 01.28.2025 - Opthea Investor Day - New York City

Recent Filings

  • 01.13.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
  • 01.13.2025 - EX-99.1 EX-99.1

MELBOURNE, Australia, andPrinceton, N.J.,Oct. 10, 2024(GLOBE NEWSWIRE) --Opthea Limited(ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be highlighted during the Innovate Retina Meeting onOctober 17, 2024, inChicago, Illinois.

David Boyer, MD, will present an update on Opthea’s wet AMD program, including highlights of the unmet medical need in wet AMD, the sozinibercept Phase 2b trial results, and the Phase 3 program designed to assess superiority in visual acuity of the combination therapy with sozinibercept over anti-VEGF-A monotherapy.

Details are as follows:

Session 4: New Routes and New MoleculesTiming:Thursday, October 17, 2024,5:27 PM CTPresentation: Update on OPT-302 (sozinibercept)Presenter:David S. Boyer, MDAgenda:https://retinainnovate.com/agenda/

Innovate Retina focuses exclusively on game-changing innovations in medical and surgical retina care, including current management of age-related macular degeneration (AMD) and diabetic retinopathy, ocular imaging, gene therapy, ocular inflammation, surgical technologies, ocular oncology, and the latest advances in retinal pharmacotherapy.

AboutOpthea

Opthea(ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST,NCT04757636, and ShORe,NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

To learn more, visit our website atwww.opthea.comand follow us onXandLinkedIn.

Authorized for release to ASX byFrederic Guerard, CEO

Investor Inquiries

PJ KelleherLifeSci Advisors, LLCEmail:pjkelleher@lifesciadvisors.comPhone: 617-430-7579

Media Inquiries

Silvana Guerci-LenaNorthStream Global PartnersEmail:silvana@nsgpllc.com

Join our email database to receive program updates:Tel: +61 (0) 3 9826 0399, Email:info@opthea.comWeb:www.opthea.com

Source:Opthea Limited

Primary Logo

Source: Opthea Limited

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com